Stockreport

Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update

Spero Therapeutics, Inc.  (SPRO) 
Last spero therapeutics, inc. earnings: 3/16 08:45 am Check Earnings Report
US:NASDAQ Investor Relations: investors.sperotherapeutics.com/overview
PDF Phase 2a proof-of-concept study of SPR720 for the treatment of Nontuberculous Mycobacterial Pulmonary Disease (NTM-PD) did not meet its primary endpoint, based on planne [Read more]